• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Apollo Endosurgery to Participate in Upcoming Investor Conferences

    11/7/22 9:00:00 AM ET
    $APEN
    Industrial Specialties
    Health Care
    Get the next $APEN alert in real time by email

    AUSTIN, TX / ACCESSWIRE / November 7, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that its senior management team will host investor meetings at four investor conference events during November and December 2022.

    Event: Stifel 2022 Healthcare Conference
    Date: Wednesday, November 16, 2022
    Presentation: 2:25 p.m. Eastern Time; 1x1 meetings available
    Location: Lotte New York Palace Hotel, New York City
    Webcast: www.apolloendo.com

    Event: 13th Annual Craig-Hallum Alpha Select Conference
    Date: Thursday, November 17, 2022
    Presentation: 1x1 meetings available
    Location: Sheraton New York Times Square Hotel, New York City

    Event: Piper Sandler 34th Annual Healthcare Conference
    Date: Wednesday, November 30, 2022
    Presentation: 4:00 p.m. Eastern Time; 1x1 meetings available
    Location: Lotte New York Palace Hotel, New York City

    Event: Stifel Medtech Madness West Coast Bus Tour
    Date: Wednesday, December 14, 2022
    Presentation: 4:45 p.m. Pacific Time
    Location: Rosewood Sand Hill Hotel, Menlo Park, CA

    For more information about scheduling a one-on-one meeting with management, please contact your institutional sales representative at the respective conference host or Matt Kreps, Investor Relations for Apollo Endosurgery, at [email protected].

    About Apollo Endosurgery, Inc.

    Apollo Endosurgery, Inc. is a medical technology company focused on development of next-generation, minimally invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications, and weight loss as a treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch® Endoscopic Suturing System, the OverStitch SxTM Endoscopic Suturing System, X-Tack® Endoscopic HeliX Tacking System, the ORBERA® Intragastric Balloon, X-Tack® Endoscopic HeliX Tacking System, as well as the Apollo ESGTM, Apollo ESG SxTM, Apollo REVISETM and Apollo REVISE SxTM Systems.

    Apollo's common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

    Contact:

    Apollo Endosurgery, Inc.
    Jeff Black, 512-279-5126
    [email protected]

    Darrow Associates Investor Relations
    Matt Kreps, 214-597-8200
    [email protected]

    SOURCE: Apollo Endosurgery, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/724154/Apollo-Endosurgery-to-Participate-in-Upcoming-Investor-Conferences

    Get the next $APEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APEN

    DatePrice TargetRatingAnalyst
    1/4/2023$10.00Buy → Hold
    Stifel
    11/30/2022$14.00 → $10.00Buy → Hold
    Lake Street
    2/23/2022$12.00 → $10.00Buy
    Stifel
    12/15/2021$13.00Outperform
    Cowen & Co.
    12/9/2021$12.00Buy
    Stifel
    9/9/2021$15.00Overweight
    Stephens
    More analyst ratings

    $APEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apollo Endosurgery downgraded by Stifel with a new price target

      Stifel downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00

      1/4/23 7:13:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery downgraded by Lake Street with a new price target

      Lake Street downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00 from $14.00 previously

      11/30/22 9:24:28 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Stifel reiterated coverage on Apollo Endosurgery with a new price target

      Stifel reiterated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      2/23/22 8:47:05 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      5/8/23 11:07:57 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13D/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 8:50:48 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Apollo Endosurgery Inc.

      SC 13G - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 4:00:12 PM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mcgaughy R Kent Jr

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:15:52 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Cpmg Inc

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:13:25 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Barr John R

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 7:56:41 PM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $APEN
    Leadership Updates

    Live Leadership Updates

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity

      MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric DevicesAUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices on December 5.(3) These milestones come only months after Apollo received FDA

      12/13/22 7:30:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to be Acquired by Boston Scientific

      Boston Scientific to acquire Apollo for $10.00 per share in cashAUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] This transaction has been unanimously approved by the Apollo Board of Directors.The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price

      11/29/22 7:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • MIMEDX Announces Leadership Transition

      K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w

      9/6/22 7:00:00 AM ET
      $APEN
      $MDXG
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Apollo Endosurgery Appoints Jeannette Bankes to Board of Directors

      Veteran Brings 30 Years of Multinational Healthcare Leadership ExperienceAUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the Global Surgical Franchise at Alcon, a worldwide developer, manufacturer and marketer of eye care medical devices and ophthalmic products."Jeannette Bankes is a seasoned healthcare executive and board member known for applying her tremendous insight, experi

      4/4/22 7:15:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery Appoints Keely Scamperle as Vice President of Reimbursement and Market Access

      Veteran Leader Brings 25 Years of Global Medical Device ExperienceAUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022."At Apollo, we are addressing large unmet clinical needs in both gastroenterology and weight loss. We understand that developing products and procedures is only one component, and that facilitating patient access is a key element to successfully developing these markets," said Chas McKhann, president and CEO of A

      1/18/22 7:45:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Financials

    Live finance-specific insights

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

      AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audi

      10/18/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

      AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only op

      7/21/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Apollo Endosurgery Inc.

      15-12G - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/14/23 10:24:35 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:16 AM ET
      $APEN
      Industrial Specialties
      Health Care